Patents by Inventor Svetlana O. Doronina

Svetlana O. Doronina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 7964567
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 21, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 7964566
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 21, 2011
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE
    Publication number: 20110064753
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 17, 2011
    Applicant: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
  • Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
    Patent number: 7851437
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: December 14, 2010
    Assignee: Seattle Genetics Inc.
    Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
  • Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
    Patent number: 7829531
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: November 9, 2010
    Assignee: Seattle Genetics Inc.
    Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
  • METHODS OF TREATING DRUG-RESISTANT CANCERS
    Publication number: 20100260786
    Abstract: Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided.
    Type: Application
    Filed: April 19, 2010
    Publication date: October 14, 2010
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Charles G. Cerveny, Alan F. Wahl
  • Antibody drug conjugate metabolites
    Patent number: 7750116
    Abstract: Methods of treating a refractory or drug resistant cancer, cell proliferative disorder and tumor cells are provided. Also provided are antibody drug conjugate metabolites.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: July 6, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Stephen C. Alley
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 7745394
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: June 29, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE
    Publication number: 20100062008
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: November 18, 2009
    Publication date: March 11, 2010
    Applicant: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
  • Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
    Patent number: 7659241
    Abstract: Compounds and compositions are disclosed in which a Drug unit (D) is linked to a Ligand unit (L). In an exemplary embodiment, the compound is of the formula LAa-Ww-Yy-D)p??Ia or a pharmaceutically acceptable salt thereof, where A is a stretcher unit, W is an amino acid unit, Y is a spacer unit, D is of the formula and a, w, y, p and R2-R10 are as disclosed in the specification. Methods for treating cancer, autoimmune disease, and infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: February 9, 2010
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
  • Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
    Publication number: 20090324621
    Abstract: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: March 20, 2009
    Publication date: December 31, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Peter D. Senter, Svetlana O. Doronina, Brian E. Toki
  • HUMANIZED ANTI-CD40 ANTIBODIES AND THEIR METHODS OF USE
    Publication number: 20090181015
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Application
    Filed: May 26, 2006
    Publication date: July 16, 2009
    Applicants: SEATTLE GENETICS, INC., GENENTECH, INC.
    Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
  • Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus
    Publication number: 20090111756
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 7, 2006
    Publication date: April 30, 2009
    Applicant: Seattle Genectics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline, Scott Jeffrey, Peter D. Senter, Damon Meyer
  • Monomethylvaline compounds capable of conjugation to ligands
    Patent number: 7498298
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: March 3, 2009
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20090047296
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 19, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus
    Publication number: 20090018086
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
    Type: Application
    Filed: July 7, 2006
    Publication date: January 15, 2009
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline
  • Auristatins Having an Aminobenzoic Acid Unit at the N Terminus
    Publication number: 20080300192
    Abstract: Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands.
    Type: Application
    Filed: November 14, 2005
    Publication date: December 4, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana o. Doronina, Brian A. Mendelsohn
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20080248051
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: October 9, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20080248053
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: October 9, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer
  • MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
    Publication number: 20080226657
    Abstract: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: August 3, 2007
    Publication date: September 18, 2008
    Applicant: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Peter D. Senter, Brian E. Toki, Allen J. Ebens, Toni Beth Kline, Paul Polakis, Mark X. Sliwkowski, Susan D. Spencer